Back to Search Results

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.

University of California San Francisco Medical Center, San Francisco, CA, USA. CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA. Sarah Cannon BMT Program, Nashville, TN, USA. University of Wisconsin Carbone Cancer Center, Madison, WI, USA. Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain. Texas Transplant Institute, San Antonio, TX, USA. Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK. University of Cincinnati, Cincinnati, OH, USA. Fred Hutchinson Cancer Research Center, Nashville, TN, USA. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Mayo Clinic Rochester, Rochester, MN, USA. Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Royal Adelaide Hospital, Adelaide, SA, Australia. Hospital Universitario Clementinio Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Division of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, FL, USA. Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Cancer Transplant Institute, Virginia G. Piper Cancer Center, Scottsdale, AZ, USA. Arizona Oncology, Scottsdale, AZ, USA. Ohio State Medical Center, Columbus, OH, USA. Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, USA. City of Hope National medical Center, Duarte, CA, USA. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Bone marrow transplantation. 2017;(12):1616-1622
Full text from:

Other resources

Abstract

Autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) patients with renal insufficiency (RI) is controversial. Patients who underwent AHCT for MM between 2008 and 2013 were identified (N=1492) and grouped as normal/mild (⩾60 mL/min), N=1240, moderate (30-59), N=185 and severe RI (<30), N=67 based on Modification of Diet in Renal Disease. Multivariate analyses of non-relapse mortality (NRM), relapse, PFS and overall survival (OS) were performed. Of the 67 patients with severe RI, 35 were on dialysis prior to AHCT. Patients received melphalan 200 mg/m2 (Mel 200) in 92% (normal/mild), 75% (moderate) and 33% (severe) RI; remainder received 140 mg/m2 (Mel 140). Thirty four of 35 patients with severe RI achieved post-AHCT dialysis independence. The 5-year PFS for normal, moderate and severe RI was 35 (95% CI, 31-38)%, 40 (31-49)% and 27 (15-40)%, respectively, (P=0.42); 5-year OS for normal, moderate and severe RI was 68 (65-71)%, 68 (60-76)% and 60 (46-74)%, respectively, (P=0.69). With moderate RI, 5-year PFS for high-dose melphalan 140 mg/m2 was 18 (6-35)% and for Mel 200 was 46 (36-57)% (P=0.009). With severe RI, 5-year PFS Mel 140 was 25 (11-41) % and for Mel 200 was 32 (11-58)% (P=0.37). We conclude that AHCT is safe and effective in patients with MM with RI.

Methodological quality

Publication Type : Multicenter Study

Metadata